156 related articles for article (PubMed ID: 38723038)
1. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract][Full Text] [Related]
2. Liposomal delivery of CRISPR/Cas9.
Zhen S; Li X
Cancer Gene Ther; 2020 Aug; 27(7-8):515-527. PubMed ID: 31676843
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer.
Camargo JA; Viana NI; Pimenta R; Guimarães VR; Dos Santos GA; Candido P; Ghazarian V; Romão P; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Trarbach EB; Reis ST
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834295
[TBL] [Abstract][Full Text] [Related]
4. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
5. In Vivo CRISPR/Cas9-Based Targeted Disruption and Knockin of a Long Noncoding RNA.
Cheng X; Peters ST; Pruett-Miller SM; Saunders TL; Joe B
Methods Mol Biol; 2021; 2254():305-321. PubMed ID: 33326084
[TBL] [Abstract][Full Text] [Related]
6. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: A novel paradigm for precision oncology.
Mahato RK; Bhattacharya S; Khullar N; Sidhu IS; Reddy PH; Bhatti GK; Bhatti JS
J Biotechnol; 2024 Jan; 379():98-119. PubMed ID: 38065367
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research.
Zhen S; Li X
Hum Gene Ther; 2019 Jan; 30(1):3-9. PubMed ID: 30045635
[TBL] [Abstract][Full Text] [Related]
8. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.
Wang X; Hayes JE; Xu X; Gao X; Mehta D; Lilja HG; Klein RJ
Gene; 2021 Feb; 768():145265. PubMed ID: 33122083
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer.
Zhen S; Hua L; Liu YH; Sun XM; Jiang MM; Chen W; Zhao L; Li X
Oncotarget; 2017 Feb; 8(6):9634-9646. PubMed ID: 28038452
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model.
Ye R; Pi M; Cox JV; Nishimoto SK; Quarles LD
J Exp Clin Cancer Res; 2017 Jun; 36(1):90. PubMed ID: 28659174
[TBL] [Abstract][Full Text] [Related]
11. SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome.
Vemuri S; Srivastava R; Mir Q; Hashemikhabir S; Dong XC; Janga SC
Methods; 2020 Jun; 178():104-113. PubMed ID: 31494246
[TBL] [Abstract][Full Text] [Related]
12. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Haeussler M; Concordet JP
J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
[TBL] [Abstract][Full Text] [Related]
13. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
Batır MB; Şahin E; Çam FS
Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA tagging and expression manipulation via CRISPR/Cas9-mediated targeted insertion.
Cheng TL; Qiu Z
Protein Cell; 2018 Sep; 9(9):820-825. PubMed ID: 28875452
[No Abstract] [Full Text] [Related]
18. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
19. Tuning the Expression of Long Noncoding RNA Loci with CRISPR Interference.
Stojic L
Methods Mol Biol; 2020; 2161():1-16. PubMed ID: 32681501
[TBL] [Abstract][Full Text] [Related]
20. Genome Editing with CRISPR-Cas9: A Budding Biological Contrivance for Colorectal Carcinoma Research and its Perspective in Molecular Medicine.
Ray SK; Mukherjee S
Curr Mol Med; 2021; 21(6):462-475. PubMed ID: 33213345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
